Back to top
more

Dentsply Sirona (XRAY)

(Delayed Data from NSDQ)

$14.05 USD

14.05
4,310,210

-0.26 (-1.82%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $14.04 -0.01 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 246)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

DENTSPLY SIRONA (XRAY) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) first-quarter results are likely to reflect strong performance at Technologies & Equipment business.

Zacks Equity Research

Analysts Estimate Dentsply International (XRAY) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Dentsply (XRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Now

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woes persist.

Zacks Equity Research

Why Is Dentsply (XRAY) Down 8.5% Since Last Earnings Report?

by Zacks Equity Research

Dentsply (XRAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Should Value Investors Pick DENTSPLY SIRONA (XRAY) Stock?

by Zacks Equity Research

Let's see if DENTSPLY SIRONA (XRAY) stock is a good choice for value-oriented investors right now from multiple angles.

Zacks Equity Research

Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Now

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woes persist.

Zacks Equity Research

Company News for Mar 1, 2022

by Zacks Equity Research

Companies In The News Are: JLL, TGNA, XRAY, VTRS.

Zacks Equity Research

DENTSPLY SIRONA (XRAY) Q4 Earnings & Revenues Miss Estimates

by Zacks Equity Research

Despite a year-over-year decline in both earnings and revenues, DENTSPLY SIRONA's (XRAY) fourth-quarter results benefit from Technologies & Equipment business.

Zacks Equity Research

Dentsply International (XRAY) Misses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Dentsply (XRAY) delivered earnings and revenue surprises of -3.80% and 3.59%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Should You Buy Dentsply Sirona (XRAY) Ahead of Earnings?

by Zacks Equity Research

Dentsply Sirona (XRAY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

Merit Medical (MMSI) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Merit Medical (MMSI) delivered earnings and revenue surprises of 42% and 3.17%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

DENTSPLY SIRONA (XRAY) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) fourth-quarter results are likely to reflect strong segmental performance.

Zacks Equity Research

Dentsply International (XRAY) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

by Zacks Equity Research

Dentsply (XRAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

AMN Healthcare (AMN) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

AMN Healthcare's (AMN) fourth-quarter results are likely to reflect solid demand in some of the areas of its business.

Zacks Equity Research

OPKO Health (OPK) to Post Q4 Earnings: What's in the Cards?

by Zacks Equity Research

OPKO Health's (OPK) fourth-quarter results are likely to reflect strength in Rayaldee.

Zacks Equity Research

What's in Store for West Pharmaceutical's (WST) Q4 Earnings?

by Zacks Equity Research

West Pharmaceutical's (WST) fourth-quarter results are likely to reflect strength in the Proprietary Products business.

Zacks Equity Research

Baxter (BAX) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Baxter's (BAX) fourth-quarter results are likely to reflect growth in its Acute Therapies business.

Zacks Equity Research

Why the Earnings Surprise Streak Could Continue for Dentsply (XRAY)

by Zacks Equity Research

Dentsply (XRAY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Now

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woes persist.

Trina Mukherjee headshot

3 Medical Products Stocks Poised to Beat This Earnings Season

by Trina Mukherjee

The Medical Products companies' Q4 results are likely to reflect base business recovery. Let's see how BAX, HSIC, and XRAY are poised ahead of their earnings releases.

Zacks Equity Research

DaVita's (DVA) Collaboration to Aid in Kidney Care Needs

by Zacks Equity Research

DaVita's (DVA) work with transplant providers and kidney doctors is likely to slow CKD progression and bolster access to home dialysis and kidney transplantation.

Zacks Equity Research

Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Now

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woes persist.

Zacks Equity Research

DENTSPLY SIRONA's (XRAY) New Alliance to Boost Digital Dentistry

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) and 3Shape extend their partnership to simplify digitally oriented workflows for dentists and dental technicians.

Zacks Equity Research

Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Now

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woe persists.

Zacks Equity Research

DENTSPLY SIRONA (XRAY) Q3 Earnings & Revenues Beat Estimates

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) third-quarter results benefit from strong segmental performance.